Announced Action for May 7, 2002

The Commission has approved a third extension of a time period concerning a matter involving Baxter International, Inc. (Baxter). Under the order in Docket No. C-3726, which concerned Baxter's acquisition of Immuno International AG, Baxter was required to contract manufacture the Autoplex Factor VIII Inhibitor Treatments for NABI (the acquiring company) for a period not to exceed three years from the date the company's divestiture application was approved, unless extended by the FTC. The divestiture approval was granted on May 8, 1997, and the divestiture was completed on May 16, 1997. The Commission's approval in the current matter, which was requested by the trustee overseeing the divestiture process, extends by 12 months, until May 8, 2003, the time that NABI has to obtain all FDA approvals to manufacture Baxter's Factor VIII Inhibitor Treatments. The Commission previously granted 12-month extensions on April 30, 2001 and May 9, 2000. The vote to approve the time period extension was 5-0. (FTC Docket No. C-3726; staff contact is Elizabeth A. Piotrowski, 202-326-2623; see press releases dated December 19, 1996; February 21, March 28, and May 13, 1997; May 9, 2000; and April 30, 2001.)

Copies of the documents mentioned in this release are available from the FTC's Web site at http://www.ftc.gov  and also from the FTC's Consumer Response Center, Room 130, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580. Call toll-free: 1-877-FTC-HELP.